Pharma: Page 2


  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    CAR-T developers respond to FDA black box warning

    Despite a recent safety warning from the FDA, companies such as BMS and J&J stress that the benefits of their cancer therapies still outweigh the risks.

    By Kelly Bilodeau • Jan. 30, 2024
  • A blood sample of HER2 for breast cancer diagnosis.
    Image attribution tooltip
    Md Saiful Islam Khan via Getty Images
    Image attribution tooltip

    AstraZeneca, Daiichi aim for first pan-tumor ADC approval

    A “tumor agnostic” FDA approval for the companies’ Enhertu would break new ground for antibody-drug conjugates. 

    By Ben Fidler • Jan. 29, 2024
  • clinical trial diversity Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Clinical trial diversity

    As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

    By PharmaVoice staff
  • Amylyx CEOs
    Image attribution tooltip
    Permission granted by Amylyx
    Image attribution tooltip
    Q&A

    ‘1 plus 1 equals 3’ — the co-CEO model in pharma

    Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

    By Jan. 26, 2024
  • 2024 outlook
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The biggest questions hanging over pharma in 2024

    Key trends on the horizon in the life sciences this year.

    By Jan. 25, 2024
  • King Charles III
    Image attribution tooltip
    Dan Kitwood/Getty Images via Getty Images
    Image attribution tooltip

    King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

    The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.

    By Jan. 25, 2024
  • J&J CEO Joaquin Duato
    Image attribution tooltip
    Mike Coppola via Getty Images
    Image attribution tooltip

    J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff

    Executives on the healthcare giant’s full-year earnings call highlighted a strong cash position and incremental dealmaking as a way to get past incoming competition.

    By Jan. 24, 2024
  • MRI machine
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Breast cancer tops list of most studied diseases

    The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.

    By Kelly Bilodeau • Jan. 24, 2024
  • Coronavirus
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    The hunt for an elusive universal coronavirus vaccine

    A new study shows that a universal vaccine would lead to huge financial and mortality wins during a pandemic, but development has been slow going.

    By Alexandra Pecci • Jan. 22, 2024
  • Chris Arendt
    Image attribution tooltip
    Permission granted by Takeda Pharmaceuticals
    Image attribution tooltip

    Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention

    Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.

    By Jan. 19, 2024
  • Pharma progress
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    How to make 2024 a banner year for biopharma, despite the headwinds

    Creative thinking is the name of the game as biopharmas seek to overcome a host of challenges — and investing with purpose, building trust and embracing tech could get them there.

    By Jan. 18, 2024
  • Covid doctor
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    An enduring COVID mystery: Why some do fine and others die

    The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.

    By Alexandra Pecci • Jan. 17, 2024
  • gut microbiome
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma takes a gut check of microbiome drugs

    On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.

    By Kelly Bilodeau • Jan. 16, 2024
  • Green light
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    4 big FDA approval dates to watch in 2024

    Following a year where the FDA approved 55 new drugs, the 2024 PDUFA calendar is set with a number of potentially buzzy approvals. 

    By Alexandra Pecci • Jan. 12, 2024
  • San Francisco
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion

    Pharma execs sound off on trends and policies they’re tracking in 2024

    From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.

    By Jan. 12, 2024
  • 2024 Crystal Ball Trials
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion // Year in Preview

    PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials

    As advanced therapies and patient perspectives strengthen their foothold in R&D, pharma is poised to deliver impactful treatments in record time.

    By Jan. 11, 2024
  • Businessman touching an artificial intelligence-themed brain
    Image attribution tooltip
    Shutthiphong Chandaeng via Getty Images
    Image attribution tooltip

    Believe the hype? Mixed signals from AI’s impact on drug development

    Although AI’s failure rates in drug development still leave room for improvement, today’s missteps feed tomorrow’s successes.

    By Kelly Bilodeau • Jan. 10, 2024
  • 2024 market
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion // Year in Preview

    PharmaVoice’s Crystal Ball: Perspectives on the financial future

    Industry leaders predict what it will take for pharma to defeat its financial foes in 2024.

    By Jan. 9, 2024
  • Black patient mental health
    Image attribution tooltip
    E+ via Getty Images
    Image attribution tooltip

    How J&J is tackling a ‘secondary pandemic’ in the Black community

    J&J is leading a grassroots effort to improve mental health access and care.

    By Alexandra Pecci • Jan. 8, 2024
  • DNA vile
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Regulatory twists and turns are coming for biopharma in 2024

    New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.

    By Kelly Bilodeau • Jan. 8, 2024
  • Infectious disease
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    In the post-pandemic era, three players still dominate the infectious disease market

    While key companies maintain their grip on the space, emerging infectious disease focus areas and a handful of other players are augmenting the market.

    By Alexandra Pecci • Jan. 5, 2024
  • Wealth gap
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Pharma’s financial market will be a tale of two cities in 2024

    What can the industry expect in 2024? Some bright spots, a few bumps and “immaculate disinflation.”

    By Kelly Bilodeau • Jan. 4, 2024
  • Alzheimer's patient
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Alzheimer’s research is hot, but successful patient recruitment will determine its future

    Key strategies for bringing more patients into the clinical trial fold.

    By Kelly Bilodeau • Jan. 4, 2024
  • J&J baby powder
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Why J&J rebranded its iconic logo

    J&J’s refreshed identity provides insight into how and why pharma companies give themselves a makeover.

    By Alexandra Pecci • Jan. 3, 2024
  • pill explosion
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    10 of our most read articles in 2023

    A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.

    By Dec. 22, 2023
  • ign on Doorway for the Federal Trade Commission in Washington D.C.
    Image attribution tooltip
    LD via Getty Images
    Image attribution tooltip

    Biopharma’s FTC headache deepens with guideline shifts years in the making

    Closer scrutiny of pharma deals has made the M&A landscape trickier as a new approach seeks to expand the competitive arena.

    By Dec. 21, 2023